Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benquikium bromide is a small molecule muscarinic acetylcholine receptor antagonist developed by Beijing Bridge Biopharmaceutical. Formulated as a nasal spray, it is primarily investigated for the treatment of allergic rhinitis and postinfectious rhinitis. The drug's mechanism of action involves the competitive inhibition of muscarinic receptors in the nasal mucosa, which prevents acetylcholine from stimulating the nasal glands. This reduction in parasympathetic activity leads to a decrease in watery nasal discharge (rhinorrhea). Benquikium bromide has undergone Phase 1 and Phase 2 clinical evaluation in China to assess its safety, pharmacokinetics, and therapeutic efficacy in patients with various forms of rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benquikium bromide.